P16 (CDKN2A) Deletion
Diffuse large B-cell lymphoma (DLBCL) is the most frequent form of aggressive lymphoma and deletions of the P16 (now known as CDKN2A) locus occur in approximately one-third of DLBCL patients1.
The CDKN2A gene encodes a cyclin dependent kinase inhibitor that functions in the control of phosphorylation of Retinoblastoma (RB), a protein that is frequently hypermethylated in lymphomas2. There are two proteins produced by the CDKN2A gene, P16 and P14ARF, the latter being an alternate reading frame product. These protein products have been linked to two tumour suppressor pathways, the RB pathway and the p53 pathway. P16 inhibits phosphorylation of RB, whereas P14ARF targets MDM2, a P53 inhibitory protein, for degradation. A deletion of the CDKN2A gene would therefore disturb both pathways3.
Losses of CDKN2A are significantly associated with a shorter survival after treatment4.
1. Guney et al., Genes Chromosomes Cancer. 2012 Sep;51(9):858-67
2. Chim et al., Hum Pathol. 2007 Dec;38(12):1849-57
3. Møller et al., Leukemia. 1999 Mar;13(3):453-9
4. Jardin et al., Blood. 2010 Aug 19;116(7):1092-104
- Area of Interest*
- Lymphoma, Brain Tumour, Lung Cancer
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.